Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Mol Med Rep ; 29(5)2024 05.
Artículo en Inglés | MEDLINE | ID: mdl-38488029

RESUMEN

Cardiovascular diseases are caused by pathological cardiac remodeling, which involves fibrosis, inflammation and cell dysfunction. This includes autophagy, apoptosis, oxidative stress, mitochondrial dysfunction, changes in energy metabolism, angiogenesis and dysregulation of signaling pathways. These changes in heart structure and/or function ultimately result in heart failure. In an effort to prevent this, multiple cardiovascular outcome trials have demonstrated the cardiac benefits of sodium­glucose cotransporter type 2 inhibitors (SGLT2is), hypoglycemic drugs initially designed to treat type 2 diabetes mellitus. SGLT2is include empagliflozin and dapagliflozin, which are listed as guideline drugs in the 2021 European Guidelines for Heart Failure and the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America Guidelines for Heart Failure Management. In recent years, multiple studies using animal models have explored the mechanisms by which SGLT2is prevent cardiac remodeling. This article reviews the role of SGLT2is in cardiac remodeling induced by different etiologies to provide a guideline for further evaluation of the mechanisms underlying the inhibition of pathological cardiac remodeling by SGLT2is, as well as the development of novel drug targets.


Asunto(s)
Diabetes Mellitus Tipo 2 , Insuficiencia Cardíaca , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Animales , Humanos , Inhibidores del Cotransportador de Sodio-Glucosa 2/farmacología , Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Remodelación Ventricular , Hipoglucemiantes/farmacología , Insuficiencia Cardíaca/metabolismo
2.
Adv Sci (Weinh) ; 10(16): e2206949, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37066747

RESUMEN

Polysulfides aqueous redox flow batteries (PS-ARFBs) with large theoretical capacity and low cost are one of the most promising solutions for large-scale energy storage technology. However, sluggish electrochemical redox kinetics and nonnegligible crossover of aqueous polysulfides restrict the battery performances. Herein, it is found that the Co, Zn dual-doped N-C complex have enhanced electrochemical adsorption behaviors for Na2 S2 . It exhibits significantly electrochemical redox activity compared to the bare glassy carbon electrode. And the redox reversibility is also improved from ΔV = 210 mV on Zn-doped N-C complex to ΔV = 164 mV on Co, Zn-doped N-C complex. Furthermore, membrane-electrode assembly (MEA) based on Co, Zn-doped N-C complex is firstly proposed to enhance the redox performances and relieve the crossover in PS-ARFBs. Thus, an impressively high and reversible capacity of 157.5 Ah L-1 for Na2 S2 with a high capacity utilization of 97.9% could be achieved. Moreover, a full cell PS-ARFB with Na2 S2 anolyte and Na4 [Fe(CN)6 ] catholyte exhibits high energy efficiency ≈88.4% at 10 mA cm-2 . A very low capacity decay rate of 0.0025% per cycle is also achieved at 60 mA cm-2 over 200 cycles.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA